3/27
08:59 am
oric
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC [Yahoo! Finance]
Medium
Report
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC [Yahoo! Finance]
3/27
08:30 am
oric
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
Medium
Report
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
3/17
05:01 pm
oric
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
High
Report
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
3/13
05:34 am
oric
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns [Yahoo! Finance]
Medium
Report
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns [Yahoo! Finance]
3/12
10:33 pm
oric
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Medium
Report
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price Volatility [Yahoo! Finance]
3/9
04:05 pm
oric
Oric Pharmaceuticals (ORIC) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Medium
Report
Oric Pharmaceuticals (ORIC) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
3/6
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
High
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/25
11:03 am
oric
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright [Yahoo! Finance]
Low
Report
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright [Yahoo! Finance]
2/24
10:58 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target raised by analysts at HC Wainwright from $23.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target raised by analysts at HC Wainwright from $23.00 to $25.00. They now have a "buy" rating on the stock.
2/24
08:54 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
High
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
2/24
07:01 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
High
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/24
03:01 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
High
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
2/23
04:05 pm
oric
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
High
Report
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
2/6
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/5
04:01 pm
oric
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Medium
Report
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
1/13
08:42 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
1/12
08:30 am
oric
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
Low
Report
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
1/9
06:10 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
1/7
06:05 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
1/6
04:05 pm
oric
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference